Dr Sridhar Siddharth - Clinical characteristics of patients with 2019-nCoV pneumonia COVID-19 2019-nCoV WuhanOutbreak Pneumonia

Updated: Clinical characteristics of patients with COVID-19

Dr Siddharth analysed the clinical characteristics of 1,689 #COVID19 patients from 21 publications, and the demographics of 2,198 2019nCoV patients.

Dr Sridhar Siddharth - Clinical characteristics of patients with 2019-nCoV pneumonia COVID-19 2019-nCoV WuhanOutbreak Pneumonia
Dr Siddharth Sridhar - 2019-nCoV COVID-19 in Hong Kong - the end of the beginning

COVID-19 in Hong Kong: the end of the beginning?

Watching the daily increase in Covid-19 cases in Hong Kong is scary. However, a more useful analysis is the ‘epidemic curve’, which looks at the date of symptom onset of cases rather than the date of case detection.

Dr Siddharth Sridhar - 2019-nCoV - COVID-19 in Hong Kong - the end of the beginning
Dr Siddharth Sridhar - 2019-nCoV COVID-19 - How do People get Covid-19 in Hong Kong 在本港,人們如何感染Covid-19

How do people get COVID-19 in Hong Kong

Dr Siddharth Sridhar, Specialist in Clinical Microbiology & Infection, looked at the main settings of Covid-19 transmission in Hong Kong (as of 20/2/2020)

Dr Siddharth Sridhar - 2019-nCoV COVID-19 - How do People get Covid-19 in Hong Kong 在本港,人們如何感染Covid-19
Dr Siddharth Sridhar - 2019-nCoV - Summary of the situation in HK 2019-nCoV在本港的概況 COVID-19 2019-nCoV WuhanOutbreak Pneumonia

2019-nCoV – Summary of the situation in HK as of Feb 6, 2020

Dr Siddharth Sridhar provides a brief overview on the infections with 2019-nCoV in Hong Kong as of Feb 6, 2020. Are they imported cases, local transmissions? And if locally transmitted how closely are the patients related?

Dr Siddharth Sridhar - 2019-nCoV - Summary of the situation in HK 2019-nCoV在本港的概況 COVID-19 2019-nCoV WuhanOutbreak Pneumonia
Dr Sridhar Siddharth - How infectious is novel coronavirus 2019 nCoV 新型冠狀病毒 2019-nCoV 的傳染性有多高 COVID-19 2019-nCoV WuhanOutbreak Pneumonia

How infectious is novel coronavirus (2019-nCoV)

Dr Siddharth Sridhar describes the basic reproduction number – a measure of how ‘infectious’ a pathogen is and how likely it is to spread through a community – for 2019-nCoV, and compares this with the early phases of the SARS and measles outbreaks.

Dr Sridhar Siddharth - How infectious is novel coronavirus 2019 nCoV 新型冠狀病毒 2019-nCoV 的傳染性有多高 COVID-19 2019-nCoV WuhanOutbreak Pneumonia
Dr Siddharth Sridhar - How stable are coronaviruses in the environment? 2019-nCoV 冠狀病毒在環境中的穩定性 COVID-19 2019-nCoV WuhanOutbreak Pneumonia

2019-nCoV: how stable are coronaviruses in the environment?

Dr Siddharth Sridhar, looked at how stable coronaviruses are on a variety of environmental surfaces, and provides recommendations to prevent infection with 2019-nCoV.

Dr Siddharth Sridhar - How stable are coronaviruses in the environment? 2019-nCoV 冠狀病毒在環境中的穩定性 COVID-19 2019-nCoV WuhanOutbreak Pneumonia
Dr Sridhar Siddharth - Who gets severe novel coronavirus (2019-nCoV) infection COVID-19 2019-nCoV WuhanOutbreak Pneumonia

Who gets severe novel coronavirus (2019-nCoV) infection?

Here, I examined the data of 28 patients from 5 publications who had severe pneumonia due to 2019-nCoV requiring ICU admission and/or resulting in death.

Dr Sridhar Siddharth - Who gets severe novel coronavirus (2019-nCoV) infection COVID-19 2019-nCoV WuhanOutbreak Pneumonia
Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?

UPPSALA, Sweden, April 24, 2019 /PRNewswire/ — Researchers of the Erasmus University Medical Center in Rotterdam − the Netherlands, consider that the synthetic and fully resorbable TIGR® Matrix surgical mesh (Novus Scientific AB, Uppsala − Sweden) may reduce frequent risks related to the surgical repair of Sportsman’s hernia.

Can a novel, temporary, and fully resorbable surgical implant improve the outcome of common hockey and soccer injuries?
FDA approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. More Information.  July 31, 2018.

Lusutrombopag FDA approved for thrombocytopenia in adult chronic liver disease patients

On the 31st of July 2018, the FDA approved lusutrombopag (Mulpleta®, Shionogi) for thrombocytopenia in adult chronic liver disease (CLD) patients scheduled for an invasive medical or dental procedure.

FDA approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure. More Information.  July 31, 2018.